Option chain shows key data for hhgregg Inc's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for hhgregg Inc.

hhgregg Inc (OTC:HGGGQ) Stock, Option Chain

Analyst Color

Earnings

News

Penny Stocks

Price Target

Reiteration

Analyst Ratings

AMZN

HGGGQ

Best Buy Co Inc (NYSE: BBY) reported better-than-expected results for its July quarter, and there are a number of catalysts to drive shares “to new highs,” according to CFRA.

After Best Buy&#39;s Q2 Beat, CFRA Says Retailer Has Catalysts To Drive Stock

Movers

Best Buy Estimated To Pick Up 20% In Market Share As hhgregg Closes Up Shop

Long Ideas

Trading Ideas

Best Buy Would Be Major Beneficiary Of An hhgregg Liquidation

hhgregg Inc

Baird analyst Colin Sebastian maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Outperform and raises the price target from $44 to $51.

CART

Baird Maintains Outperform on Maplebear, Raises Price Target to $51

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $6 price target.

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

Guidance

Management

PLUG

Plug Power Hosts 2024 Plug Symposium, Targets ~30% CAGR For Energy And Applications Businesses From 2025 To 2030; Appoints Sanjay Shrestha As New President

Sound Point Meridian Capital, Inc. Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPMC#NYSE">SPMC</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.57 by 50.88 percent. The company reported quarterly sales of $17.46 million which beat the analyst consensus estimate of $16.51 million by 5.74 percent.

Earnings Beats

SPMC

Sound Point Meridian Capital, Inc. Common Stock Q3 EPS $0.86 Beats $0.57 Estimate, Sales $17.46M Beat $16.51M Estimate

Baird analyst Colleen Kusy maintains Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) with a Outperform and raises the price target from $50 to $65.

SYRE

Baird Maintains Outperform on Spyre Therapeutics, Raises Price Target to $65

Baird analyst Catherine Ramsey maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Outperform and raises the price target from $120 to $160.

NTRA

Baird Maintains Outperform on Natera, Raises Price Target to $160

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $44 to $50.

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $50

WIIM

FLUT

Flutter Entertainment shares are trading higher after the company announced it has entered into non-discretionary arrangements with Goldman Sachs to repurchase ordinary shares.

As of Nov. 13, 2024, four stocks in the information technology sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Olo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLO#NYSE">OLO</a>)</h3>
<ul>
<li>On Nov. 7, Olo posted better-than-expected quarterly earnings. &#8220;Team Olo executed well on our top priorities in the third quarter and positioned us to complete a successful 2024. We continued to win, retain, and expand with brands, we drove further innovation across our Order, Pay, and Engage product suites — including the general availability of Olo Pay&#8217;s card-present functionality on Qu point-of-sale systems — and we delivered revenue and bottom line performance that exceeded the high-end of our guidance ranges,&#8221; said Noah Glass, Olo&#8217;s Founder and CEO. The company's stock gained around 44% over the past month and <a href="https://www.benzinga.com/quote/OLO">has a 52-week high</a> of $7.04.</li>
<li>RSI Value: 90.08</li>
<li>OLO Price Action: Shares of Olo gained 10.6% to close at $6.90 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Couchbase Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>)</h3>
<ul>
<li>Couchbase will report financial results for its third quarter ended Oct. 31, on Tuesday, Dec. 3 after market close. The company's stock gained around 18% over the past month and has a <a href="https://www.benzinga.com/quote/BASE">52-week high</a> &lt;/em>&lt;/a> of $32.00.</li>
<li>RSI Value: 78.49</li>
<li>BASE Price Action: Shares of Couchbase gained 5.5% to close at $19.57 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</h3>
<ul>
<li>On Nov. 7, BILL Holdings reported better-than-expected first-quarter financial results and issued FY25 guidance above estimates. The company's stock jumped around 45% over the past five days and has a 52-week high is $275.52.</li>
<li>RSI Value: 90.16</li>
<li>BILL Price Action: Shares of BILL gained 3.6% to close at $89.01 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Zscaler Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>)</h3>
<ul>
<li>Zscaler will release first quarter fiscal year 2025 earnings after the closing bell on Monday, Dec. 2. The company's stock jumped around 9% over the past five days and <a href="https://www.benzinga.com/quote/ZS">has a 52-week high</a> of $259.58.</li>
<li>RSI Value: 76.64</li>
<li>ZS Price Action: Shares of Zscaler climbed 4.8% to close at $209.04 on Tuesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/41896027/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

BASE

BILL

Top 4 Tech Stocks That May Keep You Up At Night This Quarter

KMDA

Kamada Raises FY24 Adjusted EBITDA Guidance To $32M-$35M, A 12% Increase Of The Midpoint From The Previous Guidance, And Reiterates Revenue Guidance Of $158M-$162M Vs. $160.47M Estimate

SWKS

Skyworks Solutions shares are trading lower after the company reported Q4 financial results and issued Q1 revenue guidance below estimates.

TD Cowen analyst Phil Nadeau downgrades Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) from Buy to Hold.

Downgrades

SYRS

TD Cowen Downgrades Syros Pharmaceuticals to Hold

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $112 to $116.

AXSM

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $116

PDCO

Patterson Dental Supply, A Subsidiary Of Patterson Companies, Announced An Agreement In Principle Between Patterson And PDS Health To Extend Their Strategic Relationship Through The End Of 2027

Mobilicom Enters Partnership With DT Research To Jointly Promote And Market Ground Control Station Products

Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) reported quarterly losses of $(2.29) per share which beat the analyst consensus estimate of $(2.85) by 19.65 percent.

Instil Bio Q2 2024 GAAP EPS $(2.29) Beats $(2.85) Estimate

Baird analyst Michael Ha maintains Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) with a Outperform and raises the price target from $67 to $86.

ASTH

Baird Maintains Outperform on Astrana Health, Raises Price Target to $86

ALTR

Altair Signed A Collaboration Agreement With Aerospace Startup Moya Aero As Part Of Altair's Aerospace Startup Acceleration Program

Earnings Misses

BITF

Bitfarms Q3 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $44.853M Miss $48.842M Estimate

Benchmark analyst Josh Sullivan initiates coverage on Airship AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AISP#NASDAQ">AISP</a>) with a Buy rating and announces Price Target of $6.

Initiation

AISP

Benchmark Initiates Coverage On Airship AI Holdings with Buy Rating, Announces Price Target of $6

Comments

hhgregg Inc

hhgregg Inc (HGGGQ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga